Search Result

Results for "

LED

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Bacterial (1) CDK (1) COX (3) Cytochrome P450 (3) Endogenous Metabolite (1) Fluorescent Dye (2) Fungal (3) Glucosidase (1) HIV (1) Interleukin Related (1) Oxytocin Receptor (1) PD-1/PD-L1 (3) Ras (1) Salt-inducible Kinase (SIK) (1) TGF-beta/Smad (1) Thymidylate Synthase (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Endocrinology (2) Infection (6) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19748

LED209	Bacterial	Infection
LED209 is a potent and orally active small molecule inhibitor of the bacterial receptor QseC and a potent prodrug with high selectivity for QseC. LED209 inhibits the binding of signaling molecules to QseC. LED209 has antibacterial activity .

HY-D0367

Fluorescent Brightener 28 Calcofluor White M2R	Fluorescent Dye	Others
Fluorescent brightener 28 is a fluorescent whitening agent commonly used in the padding process of the textile industry. Fluorescent brightener 28 is capable of staining polysaccharides such as cellulose, and when the plasma membrane ruptures, it also weakly stains the cytoplasm and strongly stains the cell nucleus. Additionally, Fluorescent brightener 28 can be utilized to detect intracellular chitin in living cells. Fluorescent Brightener 28 also is a visible light emitting diode (LED)-light sensitive photoinitiator for free radical photopolymerizations .

HY-16662

Oncrasin-1	Ras Apoptosis	Cancer
Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.

HY-W750459

Fluorescent brightener 28 (Technical Grade)	Fluorescent Dye	Others
Fluorescent brightener 28 (Technical Grade) is a fluorescent whitening agent commonly used in the padding process of the textile industry. Fluorescent brightener 28 is capable of staining polysaccharides such as cellulose, and when the plasma membrane ruptures, it also weakly stains the cytoplasm and strongly stains the cell nucleus. Additionally, Fluorescent brightener 28 can be utilized to detect intracellular chitin in living cells. Fluorescent Brightener 28 also is a visible light emitting diode (LED)-light sensitive photoinitiator for free radical photopolymerizations .

HY-117948

ML399	Others	Cancer
ML399 is a second-generation probe optimized for inhibitors of menin-mixed lineage leukemia (MLL) protein-protein interactions. Screening through the Molecular Library Probe Production Network (MLPCN) led to the discovery of several chemical classes, including piperidines, which successfully led to the generation of the first-generation probe ML227. However, metabolic instability, potency, and adjuvant pharmacological activity of ML227 were identified as limiting features. To enhance the utility of menin-MLL inhibitor probes for in vivo mechanistic studies, medicinal chemistry efforts were reinvigorated using a structure-based design approach, which ultimately led to the generation of the announced probe ML399. This study describes the structure-activity relationships and properties of this series of compounds.

HY-B1970

o,p'-DDT 2,4'-DDT	Others	Endocrinology
o,p'-DDT (2,4'-DDT) is a chlorinated organic pesticide with estrogenic activity. o,p'-DDT is persistent in the environment, can accumulate in organisms and disrupt the endocrine system. o,p'-DDT is used in agriculture as a pesticide, especially for controlling insect pests. The use of o,p'-DDT has led to toxic effects in organisms, raising widespread concern about its environmental and health effects. o,p'-DDT has also led to research into its long-term effects in ecosystems .

HY-149075

MR22	Salt-inducible Kinase (SIK)	Cancer
MR22 is a potent pan-SIK (salt-inducible kinase) inhibitor. MR22 no longer exhibits activity on STE group kinases and displays excellent selectivity in a representative kinase panel. MR22-dependent SIK inhibition led to centrosome dissociation and subsequent cell-cycle arrest in ovarian cancer cells .

HY-160084

2′-Deoxy-4′-thiocytidine	Others	Cancer
2′-Deoxy-4′-thiocytidine (T-dCyd) is a novel epigenetic agent. 2′-Deoxy-4′-thiocytidine administrations led to a significant p21 increase. 2′-Deoxy-4′-thiocytidine can eradicate of tumor cells in the double-mutant xenografts .

HY-131395

N-Acetyl-Leukotriene E4 N-Acetyl-LTE4	Endogenous Metabolite	Cardiovascular Disease
N-Acetyl-Leukotriene E4 (N-Acetyl-LTE4) is a metabolite of Leukotriene E4 (LTE4) (HY-113465), which is detected in bile and urine . N-Acetyl-Leukotriene E4 produces a vasoconstriction in the mesenteric vessels which led to reduction of blood flow to the gut .

HY-130514

SMAPP1	HIV CDK	Infection
SMAPP1 is an activator of protein phosphatase-1 (PP1). SMAPP1 increases phosphorylation of CDK9’s Ser90 and Thr186 residues, but not Ser175. SMAPP1 induces HIV-1 replication, upregulates HIV-1 transcription that led to the reactivation of latent HIV-1 provirus .

HY-156078

α-Glucosidase-IN-32	Glucosidase	Metabolic Disease
α-Glucosidase-IN-32 (compound f26) is a reversible, noncompetitive and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.07 μM. α-Glucosidase-IN-32 complex with α-glucosidase through hydrogen bonds and hydrophobic interactions, led to changes in the conformation and secondary strictures of α-glucosidase and further the inhibition of the enzymatic activity. α-Glucosidase-IN-32 can be used for diabetic disease research .

HY-B1890

(±)-Catechin 1 Publications Verification rel-Cianidanol; rel-Catechuic acid	COX	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
(±)-Catechin (rel-Cianidanol) This is a green tea polyester. Catechin possesses anti-cancer activity, which has led to its demise. (±)-Catechin 具有两种forms (+)-Catechin and its reflection body (-)-Catechin. (+)-Catechin inhibitory environment-1 (COX-1) IC₅₀ 为 1.4 μM. (-)-Catechin has the effect of promoting hBM-MSC adipose cell differentiation, increasing adipose tissue, and PPARγ horizontal. (±)-Catechin has anti-diabetic, anti-hypertrophic, anti-diabetic, anti-cardiovascular, anti-infective, and liver-protecting effects.

HY-169004

CBT-295	TGF-beta/Smad Interleukin Related	Neurological Disease Inflammation/Immunology
CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .

HY-118990

Lobelane hydrochloride	Others	Neurological Disease
Lobelane hydrochloride is a biologically active compound that has the activity of inhibiting vesicular monoamine transporter-2 (VMAT2). Lobelane hydrochloride has a low affinity for nicotinic acetylcholine receptors (nAChR), thereby enhancing its selectivity for VMAT2. Synthetic structural changes of lobelane hydrochloride have led to some related analogs that show mild changes in affinity for VMAT2. The most potent synthetic lobelane hydrochloride obtained after structural modification has a K(i) value of 630 nM, showing significant VMAT2 selectivity. The biological activity of lobelane hydrochloride suggests that it has the potential to be used in the development of compounds to inhibit methamphetamine abuse .

HY-N2435

[8]-Shogaol 1 Publications Verification	COX Apoptosis	Cancer
[8]-Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC₅₀=5 μM), anti-cancer and anti-inflammatory activity. [8]-Shogaol inhibited COX-2 (IC₅₀=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC₅₀=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .

HY-15007

L 366509	Oxytocin Receptor	Endocrinology
L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists .

HY-156150

CYP51/PD-L1-IN-2	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC₅₀: 0.263 μM) and PD-L1 (IC₅₀: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .

HY-156151

CYP51/PD-L1-IN-3	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC₅₀: 0.205 μM) and PD-L1 (IC₅₀: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .

HY-156149

CYP51/PD-L1-IN-1	Fungal Cytochrome P450 PD-1/PD-L1	Infection
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC₅₀: 0.884 μM) and PD-L1 (IC₅₀: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .

HY-16638

CB 3717 PDDF	Thymidylate Synthase	Metabolic Disease
CB 3717 is a potent inhibitor of human thymidylate synthetase, competitively binding with 5,10-methylenetetrahydrofolate (Ki = 4.9 X 10(-9) M). It also competitively inhibits human dihydrofolate reductase with dihydrofolate (Ki = 2.3 X 10(-8) M). In WI-L2 human lymphoblastoid cells, CB 3717 treatment led to a significant decrease in cellular dTTP levels and a notable increase in dUMP levels, indicating a disruption in nucleotide metabolism. The growth-inhibitory effect of CB 3717 was reversed by thymidine supplementation, demonstrating that thymidylate synthetase became rate-limiting in the presence of this compound. Delayed thymidine supplementation beyond 8 hours resulted in severe cytotoxicity, underscoring the critical timing of nucleotide rescue strategies in CB 3717-treated cells .

HY-N2435R

[8]-Shogaol (Standard)	COX Apoptosis	Cancer
-Shogaol (Standard) is the analytical standard of -Shogaol. This product is intended for research and analytical applications. -Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC₅₀=5 μM), anti-cancer and anti-inflammatory activity. -Shogaol inhibited COX-2 (IC₅₀=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC₅₀=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library	1,486 compounds
Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc. MCE offers a unique collection of 1,486 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Anti-Alzheimer's Disease Compound Library

1,486 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1,486 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L036

Covalent Screening Library	1,710 compounds
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 1,710 small molecules including identified covalent inhibitors and other bioactive molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, Sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

Covalent Screening Library

1,710 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 1,710 small molecules including identified covalent inhibitors and other bioactive molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, Sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

HY-L908

Lead-like Covalent Screening Library	500 compounds
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE Lead-like Covalent Screening Library offers a valuable resource of 500 lead-like compounds with commonly used covalent warheads. These warheads, such as acrylamide, activated terminal alkyne, acyloxymethyl ketone, and boronic acid, are capable of reacting with specific amino acid residues, including cysteine, lysine, serine, and histidine. The inclusion of these reactive warheads in the library allows researchers to explore the potential of covalent inhibition, a powerful approach in drug discovery.

Lead-like Covalent Screening Library

500 compounds

MCE Lead-like Covalent Screening Library offers a valuable resource of 500 lead-like compounds with commonly used covalent warheads. These warheads, such as acrylamide, activated terminal alkyne, acyloxymethyl ketone, and boronic acid, are capable of reacting with specific amino acid residues, including cysteine, lysine, serine, and histidine. The inclusion of these reactive warheads in the library allows researchers to explore the potential of covalent inhibition, a powerful approach in drug discovery.

HY-L036P

Covalent Screening Library Plus	3,023 compounds
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 3,023 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Covalent Screening Library Plus

3,023 compounds

MCE covalent inhibitor library contains 3,023 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

HY-L075

Anti-Lung Cancer Compound Library	1,990 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 1,990 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Anti-Lung Cancer Compound Library

1,990 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1,990 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-D0367

Fluorescent Brightener 28 Calcofluor White M2R	Fluorescent Dyes/Probes
Fluorescent brightener 28 is a fluorescent whitening agent commonly used in the padding process of the textile industry. Fluorescent brightener 28 is capable of staining polysaccharides such as cellulose, and when the plasma membrane ruptures, it also weakly stains the cytoplasm and strongly stains the cell nucleus. Additionally, Fluorescent brightener 28 can be utilized to detect intracellular chitin in living cells. Fluorescent Brightener 28 also is a visible light emitting diode (LED)-light sensitive photoinitiator for free radical photopolymerizations .

Fluorescent Brightener 28

Calcofluor White M2R

Fluorescent Dyes/Probes

Fluorescent brightener 28 is a fluorescent whitening agent commonly used in the padding process of the textile industry. Fluorescent brightener 28 is capable of staining polysaccharides such as cellulose, and when the plasma membrane ruptures, it also weakly stains the cytoplasm and strongly stains the cell nucleus. Additionally, Fluorescent brightener 28 can be utilized to detect intracellular chitin in living cells. Fluorescent Brightener 28 also is a visible light emitting diode (LED)-light sensitive photoinitiator for free radical photopolymerizations .

Cat. No.	Product Name	Target	Research Area

HY-P10629

PSMα2	Peptides	Inflammation/Immunology
PSMα2 is a potent PSM (phenol-soluble modulin) peptide toward mouse neutrophils, led to strong influx of leukocytes .

HY-P2048

MOTS-c (human)	Peptides	Others
MOTS-c (human) is a biological active peptide. (Recent advances in high-resolution sequencing have led to the discovery of unique peptides derived from mitochondrial genome.1-2 Currently 8 peptides are identified: humanin, mitochondrial open reading frame of the 12S tRNA-c (MOTS-c), and six small humanin-like peptides (SHLP1-6). 1-2 All of these peptides are released into cytosol from mitochondria and associate with increased longevity and cell viability, reduced apoptosis, and other beneficial functions. 1-3 MOTS-c was found to reduce insulin resistance, decrease obesity, and promote homeostasis.)

(±)-Catechin 1 Publications Verification rel-Cianidanol; rel-Catechuic acid	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Source classification Plants Camellia sinensis (L.) O. Ktze. Infection Phenols Polyphenols Inflammation/Immunology Disease Research Fields Theaceae	COX
(±)-Catechin (rel-Cianidanol) This is a green tea polyester. Catechin possesses anti-cancer activity, which has led to its demise. (±)-Catechin 具有两种forms (+)-Catechin and its reflection body (-)-Catechin. (+)-Catechin inhibitory environment-1 (COX-1) IC₅₀ 为 1.4 μM. (-)-Catechin has the effect of promoting hBM-MSC adipose cell differentiation, increasing adipose tissue, and PPARγ horizontal. (±)-Catechin has anti-diabetic, anti-hypertrophic, anti-diabetic, anti-cardiovascular, anti-infective, and liver-protecting effects.

[8]-Shogaol 1 Publications Verification	Zingiber officinale Roscoe Structural Classification Monophenols Classification of Application Fields Source classification Phenols Plants Disease Research Fields Zingiberaceae Cancer	COX Apoptosis
[8]-Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC₅₀=5 μM), anti-cancer and anti-inflammatory activity. [8]-Shogaol inhibited COX-2 (IC₅₀=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC₅₀=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .

[8]-Shogaol (Standard)	Zingiber officinale Roscoe Structural Classification Monophenols Source classification Phenols Plants Zingiberaceae	COX Apoptosis
-Shogaol (Standard) is the analytical standard of -Shogaol. This product is intended for research and analytical applications. -Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC₅₀=5 μM), anti-cancer and anti-inflammatory activity. -Shogaol inhibited COX-2 (IC₅₀=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC₅₀=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks